Subcutaneous Biologics: The Future of Self-Administered Drug Delivery

Chronic disease has been climbing for years now, diabetes, multiple sclerosis, and rheumatoid arthritis are all trending the wrong direction across most of the world. That's pushed a lot of pharmaceutical R&D toward biologics as a treatment option, and biologics have historically leaned on parenteral administration to actually work the way they're supposed to. In practice, that's meant to be patients showing up for repeat intravenous infusions, over and over, for conditions that don't go away.

That gets expensive fast, and not just in terms of the drug itself. Hospital visits add up. Transportation adds up. For someone managing a lifelong condition, the logistics of treatment can end up costing almost as much as the medicine does.

Subcutaneous delivery is the industry's answer to that problem. Instead of an IV line and a clinical visit, patients get devices that let them administer the drug themselves, under the skin, often at home. Beyond the obvious convenience, this kind of self-administration has a real, measurable effect on how consistently patients actually stick with their treatment plans. At CMI Consulting, we've spent a fair amount of time looking at this shift, because it's reshaping how a huge chunk of the biologics industry thinks about drug delivery, not just a niche corner of it.

What's Actually Approved Right Now

Looking at the current approved landscape, there are more than 175 subcutaneous biologics on the market, developed by roughly 50 companies worldwide. What stands out is how concentrated this space is at the top: large and very large pharmaceutical players make up close to 90 percent of everyone involved. That's a strong signal this field has moved past its early, experimental phase, it now takes real institutional expertise and infrastructure to compete here. AstraZeneca, Bristol-Myers Squibb, and Novo Nordisk are among the names with the deepest footholds, and most companies with approved products are still headquartered in North America.

Most of the approvals in this category actually clustered between 2011 and 2020, a genuinely active decade for the field. And proteins dominate as the drug type of choice, largely because they tend to work well with the body's existing biological processes rather than against them, which keeps adverse reactions and immune responses relatively low.

What's Still in the Pipeline

The clinical-stage side of the market looks different and, honestly, a lot more crowded. Over 340 subcutaneous biologics are currently in development across roughly 120 companies, and this segment skews toward mid-sized and smaller companies rather than the giants dominating the approved space. That's usually a sign of a market still actively expanding, with room for newer players to carve out a position. Lundbeck, R-Pharm, and UCB are among the larger names active at this stage.

In terms of how these drugs actually work, we group the mechanisms into four broad categories: inhibition, modulation, stimulation, and a smaller "other" bucket. Inhibition dominates by a wide margin, accounting for roughly 60 percent of clinical-stage subcutaneous biologics, with stimulation-based mechanisms coming in second.

The Technology Making Self-Administration Possible

Behind every subcutaneous biologic sits a delivery technology, and there are more than 40 distinct formulation technologies currently in development across more than 40 companies. Similar to the clinical pipeline, this space is dominated by mid-sized and smaller players, together accounting for close to 70 percent of the market. Most of these developers are based in North America, specifically the US, with the UK serving as Europe's main operational hub for this kind of work.

Some of the approaches being developed are genuinely inventive. AstraZeneca, for instance, has built technology around ultra-small silica particles that enable targeted delivery, particles that can be paired with both drugs and imaging agents to direct therapy precisely at specific tissue, tumors being a notable example.

Encapsulation is the dominant underlying principle across most of these technologies, and it makes sense once you think through why. Encapsulation allows a drug's release to be tailored, whether that means sustained release over time or targeted delivery to a specific site, which is exactly what's needed for biologics with short half-lives that would otherwise require frequent re-dosing.

How Companies Are Building Out Their Capabilities

Given how specialized this field is, partnerships have become a common way for companies to expand what they can actually offer. These deals typically aim to broaden a company's technology or product portfolio and bring in capabilities they don't have in house. Technology licensing agreements have emerged as the go-to structure here, more common than any other partnership model in this space.

Our Take on Where the Approved Market Is Headed

Driven mostly by growing emphasis on patient compliance and better treatment outcomes, we expect the approved subcutaneous biologics market to grow at around 5 percent annually through 2027. Antibodies currently hold the largest share of the overall market, though nucleotide-based therapies look set to grow at a notably faster clip over the forecast period.

And Where the Underlying Technology Market Is Headed

The formulation technology side of this market looks even more dynamic. Between the clear clinical advantages subcutaneous delivery offers and the rising number of licensing deals we've been tracking, our analysis points to the formulation technology market growing at an annualized rate of roughly 22.7 percent over the next decade, a considerably steeper trajectory than the approved drug market itself. North America currently holds the majority share here too, largely thanks to its advanced healthcare infrastructure and deep research capabilities, both of which matter enormously given how stringent regulatory requirements are in this space.

Where This Leaves the Industry

Subcutaneous drug delivery has real momentum behind it, and for good reason given how clearly it outperforms traditional delivery on convenience and patient experience. Devices like wearable infusion pumps, autoinjectors, pen injectors, microneedles, needle-free injectors, and large-volume injectors have all drawn serious industry attention lately, each offering its own take on making medication administration less of a burden.

As more subcutaneous biologics reach approval, demand for these delivery devices is only going to keep climbing alongside them. It's also worth noting how many pharmaceutical companies are actively reformulating drugs that were originally built for IV administration, essentially re-engineering existing products for subcutaneous delivery rather than starting from scratch. That trend alone suggests this shift isn't a passing preference, it's becoming the default expectation for how biologics get delivered going forward.